In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

Snapshot: August Highlights

A selection of articles you may have missed from August 2023, including a breakdown of CEO pay, a discussion on being out and proud in the life sciences sector, and some hopeful discourse on the investment landscape going into 2024.

Medical Device BioPharmaceutical

Trends In Life Science Disputes And The Case for Arbitration

The life sciences sector is beginning to appreciate the benefits of arbitration. Parties increasingly recognize that arbitration can be an effective, economical, confidential and business-focused mechanism to resolve the wide range of commercial disputes that arise in the sector.

Business Strategies Deals

Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market

Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.

Market Intelligence Strategy

Deals in Depth July 2023

Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.

Deals Financing

Snapshot: July Highlights

A selection of articles you may have missed from July 2023, including an interview with Abivax CEO Marc De Garidel, a roundup of biopharma dealmaking activity in the first half of 2023 and a look at Seres’ and Ferring’s launch strategies in recurrent C. diff market.

Market Intelligence BioPharmaceutical

Majority Of FDA Priority Review Vouchers Remain Unused

Infographic: An estimated 64 priority review vouchers have been issued by the US FDA since the scheme started in 2007. 25 vouchers have been claimed but 39 remain unused. Priority review vouchers do not expire and can be sold.

Approvals FDA

Deals Shaping The Industry, July 2023

In Vivo's deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in July 2023. Data provided by 

Medical Device BioPharmaceutical

Dealmaking Quarterly Statistics, Q2 2023

During Q2, biopharma merger and acquisition deal value reached $29bn and drew in $36.8bn in potential deal value from alliances. Device company M&A values reached $988m, while in vitro diagnostics and research tools players’ M&A activity totaled $450m.

Deals Market Intelligence

Financing Quarterly Statistics, Q2 2023

During Q2, biopharmas brought in an aggregate $23.8bn in financing and device company fundraising totaled $2.4bn; while in vitro diagnostic firms and research tools players raised $684m.

Deals BioPharmaceutical

Healthcare In Crisis: A Vision Of More Human And Flexible Healthcare Experiences

Staff burnout, workforce attrition and patient backlogs are testing the resiliency of health systems. Crisis is not too big a word. Against this backdrop, GE HealthCare commissioned a major report, Reimagining Better Health 2023, which suggested ways of increasing trust and confidence in healthcare provider systems as they evolve.

Medical Device Innovation

Can New Generation GLP-1s Overcome The Adherence Hurdle?

Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term. 

Market Intelligence Strategy

The E in ESG: Data Reporting To Meet Healthcare’s Sustainability Challenge

High quality data reporting will be crucial if the healthcare and life sciences sectors are to achieve net zero compliance of carbon emissions. This 12th instalment of In Vivo’s rolling E in ESG series reports on the growing body of disclosure and reporting laws and platforms.

Sustainability Medical Device

Deals in Depth: June 2023

Three $1bn+ alliances were penned in June. Topping the list was a potential $2.5bn deal under which Bausch & Lomb acquired Novartis’ Xiidra (lifitegrast ophthalmic solution) for signs and symptoms of dry eye disease; investigational compounds SAF312 (libvatrep) for chronic ocular surface pain and OJL332 for an undisclosed ophthalmic indication; plus rights to use the AcuStream delivery device in dry eye indications.

Deals Financing

Snapshot: June Highlights

A selection of articles you may have missed from May 2023, including a discussion on pharma's resilience to harsh market conditions, a comparison of productivity and R&D growth for the pharma top 30 and a dive into diversity's positive impacts on business growth.

BioPharmaceutical Business Strategies

Asian Giants Are Racing For Neuroscience Developments

China, Japan and South Korea are the top economic powerhouses of Asia. They compete not only for production industries such as electronics, but also for medical sciences. China has enormous resources compared with the two other nations.

Neurology Research & Development

Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else

Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a recent analysis of FDA approval decisions since 2021.

US States Approvals
See All